chengdu shengnuo biotechnology company: Subsidiary icatibant acetate injection obtained drug registration certificate
chengdu shengnuo biotechnology company announced on April 21 that chengdu shengnuo biotechnology company a wholly-owned subsidiary of the company, recently received the “Drug Registration Certificate” for icatibant acetate injection issued by the National Medical Products Administration.
Icatibant acetate injection is a drug developed by Shire Company and marketed abroad in 2008 for the treatment of hereditary angioedema. It was included in the “Recommended List of the First Batch of Encouraged Generic Drugs” by the National Health Commission. Its indications are adults. For acute attacks of hereditary angioedema (HAE), the company is the first domestic and foreign generic icatibant API company to submit DMF filing to the US FDA.
Other Polypeptide APIs Products
peptide synthesis companies
| Polypeptide APIs Products |
| US-DMF LIST |
| Beauty peptides |
| Chinese cGMP APIs |
| Mexico Registered APIs |
| Research Peptide APIs for Regulatory Market |
| Polypeptide Preparation |
| Kaijie bio medicine Peptide APIs |